Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Australia
Royal Prince Alfred Hospital, Camperdown, New South Wales Flinders Medical Center, Bedford Park, South Australia The Royal Melbourne Hospital, Fitzroy, Victoria Fiona Stanley Hospital, Perth, Western Australia New Zealand
Pacific Clinical Research Network - Auckland, Takapuna, Auckland